tiprankstipranks
Trending News
More News >

Noxopharm Secures Ethics Approval for Pioneering HERACLES Clinical Trial

Story Highlights
Noxopharm Secures Ethics Approval for Pioneering HERACLES Clinical Trial

Don’t Miss TipRanks’ Half-Year Sale

Noxopharm Ltd. ( (AU:NOX) ) just unveiled an announcement.

Noxopharm Limited has received approval from the Human Research Ethics Committee to commence the HERACLES clinical trial, marking a significant milestone for the company. This trial, the first of its kind in Australia, will test SOF-SKN™, a novel drug candidate targeting chronic inflammatory diseases, including cutaneous lupus erythematosus. The approval allows Noxopharm to begin recruitment and operational activities, collaborating with the Doherty Clinical Trials team in Melbourne. This development underscores Noxopharm’s strategic focus on leveraging Australian expertise in early-phase clinical trials and securing federal R&D tax benefits, potentially enhancing its market position in the biotech industry.

More about Noxopharm Ltd.

Noxopharm Limited (ASX:NOX) is a clinical-stage Australian biotech company focused on discovering and developing novel treatments for cancer and inflammation. The company leverages its specialist in-house capabilities and strategic partnerships to build a pipeline of proprietary drugs based on two technology platforms: Sofra™ for inflammation, autoimmunity, mRNA drug enhancement, and oncology, and Chroma™ for oncology.

Average Trading Volume: 84,187

Technical Sentiment Signal: Sell

Current Market Cap: A$19.58M

For a thorough assessment of NOX stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1